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1. Introduction
Asthma is a chronic inflammatory and immunologic common which associated with revers‐
able obstruction of airflow. Arab countries are with 20% prevalence rate and ambient air
pollution may contribute to rise in this rate with time. Environmental factors are known to
play an important role in the elicitation of asthma in genetically predisposed individuals.
Although there has also been an increase in the awareness among doctors to diagnose asthma,
a combination of various other factors may also be involved in the increased prevalence of
asthma. Further investigations are recommended to identify the etiologic factors contributing
to the rising prevalence of this disorder in Arab countries [1].
Asthma is common with an increasing prevalence and mortality especially in low-income and
minority populations. The National Heart, Lung, and Blood Institute (NHLBI) defined asthma
as “recurrent episodes of respiratory symptoms; variable airflow obstruction that is often reversible,
either spontaneously or with treatment; presence of airway hyper reactivity; and, importantly, chronic
airway inflammation in which many cells and cellular elements play a role, in particular, mast cells,
eosinophils, T- lymphocytes, macrophages, neutrophils, and epithelial cells”[2]
Asthma is an important worldwide health priority because of its high and increasing preva‐
lence, high morbidity and mortality, and direct and indirect costs. Asthma is with a prevalence
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of 12% of the population [3] with significant impact on quality of life and cost. [4]. The most
important thing that relialized is asthma has been associated with significant comorbidities,
especially depression [5-10]. Although stress triggered asthma symptoms, does not all of a
sudden cause a person to develop the disease of asthma. [11,12]. The course of asthma appears
to be influenced by mood and emotions and there is a high prevalence of depression or
depressive symptoms in both children and adults with asthma.[11,12]
Recent studies indicated a positive association between stress and asthma exacerbation [13].
The chronicity of asthma course and episodic recurrences may lead to development of
depression in asthmatic patients, specially in subjects with severe uncontrolled asthma [14].
Depression is associated with increased use of asthma-related urgent care services, emergency
rooms, hospitals, and unscheduled appointments for asthma. as well as a variety of unfavor‐
able asthma outcomes. Despite data on the frequency of depression in asthma and its adverse
consequences, it is generally not recognized or treated.
Combination of conventional treatment drugs with antidepressants may amliorate asthma
course and attack severity [15]. Both asthma and depression shared some biological linkage
and antidepressant may be of therapeutic benefit through induction of bronchodilatation
and  reduction  in  cytokines  production  in  asthmatic  patients  [16,17,18].  Immune  and
inflammatory responses in asthmatic patients may be modulated by antidepressants [18,19].
The ideal antidepressant to be used for treatment of asthma in combination with convention‐
al drugs should have bronchodilator and anti-inflammatory activity and non-sedating such
as tianeptine [20].
The present study was conducted to determine the therapeutic efficacy of Tianeptine in
patients with asthma. Informed cosent taken from each subject included in the study and the
study protocol was approved by the ethical committee.
Objectives: To determine the therapeutic efficacy of Tianeptine in patients with asthma.
2. Patients and methods
2.1. Study population
The study was performed on asthmatic patients. The subjects included in the study were
recruited  from  the  Habib  Hospital  outpatients  Clinic  in  the  Kingdom  of  Saudi  Arabia.
[Table 1]. The sample size in the study was 82 adult patients suffering from asthma for at
least one year duration, and their age range was from 18 to 70 years, with a mean age of
35.8 years. The diagnosis and classification of asthma was performed by specialist physi‐
cian and was established according to the National Heart Blood and Lung Institute / World
Health Organization (NHLBI/WHO) workshop on the Global Strategy for Asthma [21]. The
diseases severity classification was performed according to GIN criteria [22]. Patients were
excluded if  they were smokers,  if  they had malignancy,  heart  failure,  history of  venous
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embolisms, coronary heart disease and liver or kidney diseases..Current substance or alcohol
Abuse/dependence, MDD with psychotic features (delusions, hallucinations, disorganized
thought  processes)  or  schizophrenia  or  schizoaffective  disorder  or  if  they  had  mental
retardation or other severe cognitive impairment or if they were on current antipsychotic
or antidepressant therapy or psychotherapy. Initiation of other psychotropic medications
or psychotherapy within past 2 weeks (e.g., anxiolytics, hypnotics) and if they were pregnant
or nursing women.
Group Used drugs
Total numbers of
patient in the
group
Number of patients
completed the trial
Average of
patients age/yr
Mean [SD]
Number of
male patients
Number of
female
patients
1 Conventional 22 18 35.88[14.02] 9 9
2 Conventional+Tianeptine 21 15
36.4
[13.33] 8 7
3 Singulair+ Tianeptine 19 15 35.53[12.72] 8 7
4
Conventiona+
fexofenadine+
Tianeptine
20 17 35.7[10.85] 8 9
P value NS NS NS NS NS
Table 1. Study population
Inclusion criteria includes: Out patients; Bronchial asthma has been known at least for 1 year ;
Absene of long-term remissions of asthma (lasting more than 3 months) ; Poorly controlled
asthma, due to various reasons ; No changes in asthma medications. ; and Both male and female
2.2. Study design
This study is randomized controlled trial to evaluate the therapeutic activity of tianeptine for
treatment of asthma. The patients were distributed randomly to the groups. Patients who were
eligible for entry in the study were included and follow-up for 8 weeks. Each patient had three
visits, the first when introduce him\her in the study then the second after a month and the
third was after two months
2.3. Measurement of stress
Perceived Stress Scale (PSS)[23] was used to measure the perception of stress in our study
population. The Perceived Stress Scale is the only empirically established index of general
stress appraisal. “The PSS measures the degree to which situations in one’s life is appraised as
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stressful [24]. The PSS is not a diagnostic instrument, so there are no cut-offs. There are only
comparisons between people in a given sample relationship between PSS scores and health
behaviors and relationship among performance appraisal discomfort and belief, core self-
evaluation and perceived stress.
There are three versions of the PSS: One with 4, one with 10, and one with 14 items. The 14-
item version, which is the version that was adapted culturally to our study, as it had been used
in previous studies and, at that time. Thus, the version we used has 14 items and is rated on a
5-point Liker type scale, ranging from 0 (never) to 4 (very frequently). Scores of items 4, 5, 6, 7,
9, 10, and 13 are reversed. Higher scores correspond to higher perceived stress. Internal
consistency and factor structure data are mentioned in the introduction.[25]
2.4. Treatment schedule
The patients were distributed randomly into four groups each one include 25 patients.
Selection of patients and distribution of them in the groups will be equally matched in gender,
severity and presence of attack.
• The first group given conventional asthma treatment [SYMBICORT (budesonide and
formoterol inhalation) or SEROTID (Salmeterol, fluticasone propionate).with or without
salbutamol].
• The second group given conventional asthma treatment plus tianeptine12.5mg three times
daily
• The third group given Singulair 10mg once daily (montelukast) plus tianeptine
• The fourth group is given conventional treatment with fexofenadine180 mg once daily plus
tianeptine
2.5. Research methodolog
a. After making sure of the status of each individual from the patients have asthma and they
are eligible for this study design and did not have any of the exceptions for the study will
be admitted to one of the study groups. Informed written consent taken from all patients
included in the study.
b. Baseline  assessment  conducted  for  each  patient  at  the  time  of  enrollment  in  the
study,also recording the number of attacks suffered by the patient during the week
and the number of times where he \she wake up because of shortness of breath and
the number of  times sprays ventolen during the week and the number of  absences
from school or work during the month due to asthma and assessing the severity of
cough and the severity of breathing difficulty suffered by the patient that were divided
to  three  degrees,simple,  moderate  and  severe.  Also  study  and  record  presence  of
wheezing or not. As spirometry remains an essential diagnostic tool in assessment of
asthmatic patient But we will limit ourselves to study Peak Expiratory Flow Rate (PEFR)
because it  is a simple method of measuring airway obstruction the device is availa‐
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ble,  accessible,  and easy to use by the patient and it  will  detect moderate or severe
disease.  The simplicity of the method is its  main advantage.  It  is  measured using a
standard Wright Peak Flow Meter or mini Wright Meter. The needle must always be
reset to zero before PEF is measured. The measurement of peak expiratory flow rate
(PEFR)  three  to  four  times  allows  the  diagnosis  and  assessment  of  the  severity  of
asthma. [26].  It  will  be studied for all  patients,  and the stress and anxiety status of
patients will determined for all patients included in the study by using Perceived Stress
Scale. Arabic version of the questions set prepared and used through the study.
c. Patients evaluation performed at interval of the study and at least to attend the chest clinic
3 times during the study period.
Visit 1: Screening visit:
The following actions were taken
• take the written consent of the patient on the study after explaining all matters relating
thereto
• General medical history & physical examination.
• Study of stress and anxiety status by Complete Perceived Stress Scale
• Measure peak expiratory flow
• Complete asthma control questionnaire.
Visit 2: 4weeks after visit 1
The following actions were taken
• Baseline clinical measurements
• Complete asthma control questionnaire
• Measure peak expiratory flow
Visit 3: 4weeks after visit 2
Repeat all the actions taken in the visit 2
At each study visit the peak expiratory flow (PEF) will be performed, the best of three
measurements will be recorded [27].
2.6. Asthma control questionnaire
International guidelines for the treatment of asthma have identified that the primary clinical
goal  of  asthma management  is  to  optimise  asthma control  (minimisation  of  symptoms,
activity limitation, and bronchoconstriction and rescue β2 -agonist use) and thus reduce the
risk  of  life-threatening  exacerbations  and  long-term  morbidity.  The  Asthma  Control
Questionnaire (ACQ) was developed to meet these criteria. It measures both the adequa‐
cy of asthma control and change in asthma control, which occurs either spontaneously or
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as a result  of  treatment [28].  We have developed a schedule for each patient where the
following  questions  is  registered  for  all  visits  to  facilitate  consideration  of  the  patient's
condition fully [29].
1. In the past 4 weeks, how much of the time did your asthma keep you from getting as much
done at work, school or at home?
2. During the past 4 weeks, how often have you had attacks of shortness of breath?
3. During the past 4 weeks, how often did your asthma symptoms (wheezing, coughing, and
shortness of breath, chest tightness or pain) wake you up at night or earlier than usual in
the morning?
4. During the past 4 weeks, how often have you used your rescue inhaler or nebulizer
medication (such as salbutamol)?
5. Assessment of severity of cough, SOB.
6. Is there wheezing or no?
7. How would you rate your asthma control during the past 4 weeks?
8. Recording peak expiratory flow
2.7. Statistical analysis
SPSS package (version 17) was used for statistical analysis.
3. Results
Out of the total (82) patients with asthma included in the study, 79% (65 patients) of them
continued until the end of the study and are eligiable for analysis. The subjects suitable for
analysis are consisted of 33 men (52%) and 32 women (48%). The mean age was 35.8 years
(Table 1).
3.1. Role of conventional asthma treatment in the first group
In this study 22 patients has been selected for the first group, 18 patients (81.8%) of them
continued until the end of the study. Of the total, 9 patients were male and 9 were female and
they were given conventional asthma treatment only [SYMBICORT (budesonide and formo‐
terol inhalation) or SEROTID (Salmeterol, fluticasone propionate) with or without salbutamol].
Their results are shown in Table 3. The average age of patients was 35.8 year, average severity
of symptoms was 2.78, medication score was 3.94 and PSS value was 22.94. There was
significant clinical impact of ventolin, Symbicort and Seretide conventional in treatment of
asthma. Then average of improvement after a month was 1.94 and increased to 2.11 after 2
months period (P= 0.001) from the base line and PEFR increased from 72.6% at the time of
enrollement in the study to 83.6% at the end of the study (P=0.0001).
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Variable Mean Std. Deviation Std. Error Mean 95% Confidence interval
Age 35.89 14.02 3.31 28.92 – 42.86
Severity of asthma 2.78 1.26 0.30 2.15 – 3.41
Medication score 3.94 1.80 0.42 3.04 – 4.83
PSS Score 22.94 7.90 1.86 19.01 – 26.87
Rate
of improvement
1 month 1.93 0.24 0.06 1.74-2.13
2 month 2.11 0.47 0.11 1.83 – 2.39
P value 0.001
PEFR
Study onset 72.67 10.69 2.52 67.35 – 77.99
End of the
study 83.61 8.63 2.16 79.3 – 87.9
P value 0.0001
Table 2. Combined rates of all data for patients of Conventional treatment (group 1)
3.2. Role of conventional asthma treatment plus Tianeptine in the second group
These patients were given the same of traditional medicines which given to the first group,
but was added Tianeptine to each patients in this group. The average patients age was 36.4
year, average severity of symptoms was 3.06, medication score was 3.9 and PSS value was
22.33. The treatment lead to improvement of 1.93 after a month and this increased to 2.4 after
2 months with significant difference (P= 0.001) from the baseline. In addition, PEFR increased
from 77.4% at study enrollement to 89.13% at the end of the study (P= 0.0001).
Variable Mean Std. Deviation Std. Error Mean 95% onfidence interval
Age 36.40 13.33 3.44 29.03 – 43.76
Severity of asthma 3.07 .96 .25 2.54 – 3.60
Medication score 4.73 1.44 .37 3.93 – 5.53
PSS score 22.33 7.79 2.01 18.03 – 26.63
Rate of
improvement
1 month 1.93 .258 .067 1.74-2.13
2 month 2.40 .63 .16 2.09-2.70
P value 0.001
PEFR
Study onset 77.40 7.88 2.03 73.05 – 81.75
End of study 89.13 4.88 1.26 86.43 – 91.83
P value 0.0001
Table 3. Combined rates of all data for patients of Conventional treatment with Tianeptine [group 2]
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3.3. Role of Tianeptine ± Singulair in asthmath in the third group
These patients were given Tianeptine12.5+Singulair10mg without addition or modification of
traditional medicines. The average of patient’s age was 35.53, average severity of symptoms
was 2.46, medication score was 6, and average of PSS of this group was 23.06. The improvement
after a month was 1.00 and increased to 2.13 after 2 months (P=0.001) from the baseline.
Furthermore, average of Rate of peak expiratory flow at onset of study was 80.4% and increased
to 88.4% at the end of the study (P=0.001).
Variable Mean SD St. Error of mean 95% confidence interval
Age 35.53 12.72 3.28 28.50 – 42.56
Severity of asthma 2.47 0.92 0.24 1.96 – 2.98
Medication score 6.00 0.00 0.00 6.00 – 6.00
PSS score 23.07 5.88 1.52 19.82 – 26.32
Rate of
improvement
1 month 1.00 0.38 0.10 0.81-1.19
2 month 2.13 0.74 0.19 1.83-2.44
P value 0.001
PEFR
Study onset 80.40 5.55 1.43 77.33 – 83.47
End of study 88.40 7.34 1.89 83.34 – 92.46
P value 0.001
Table 4. Combined rates of all data for patients of Singulair with Tianeptine [group3]:
3.4. Role of conventional medicines ± fexofenadine ± tianeptine in asthma in the fourth
group
In this group, 17 patients continued until the end of the study, including 8 patients were male
and 9 were female. The patients were given the same of traditional medicines given to the first
group, but was added Tianeptine (12.5 mg) three time daily and fexofenadine (180 mg) once
daily to each patients in this group. Average of patient’s age of fourth group was 35.7, average
of severity of symptoms was 3.17, medication score was 7, and average of PSS of this group
was 26.67. The average of improvement after a month was 2.41and this increased to 2.58 after
2 month of treatment (P=0.0001). In addition, PEFR was increased to 88.41% at the end of the
study (P=0.0001)
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Variable Mean Std. Deviation Std. Error Mean 95% Confidence interval
Age 35.71 10.85 2.63 30.13 – 41.29
Severity of asthma 3.18 1.42 .35 2.45 – 3.91
Medication score 7.00 .00 .00 7.00 – 7.00
PSS score 26.65 4.65 1.13 24.26 – 29.04
Rate of
improvement
1 month 2.41 .51 .12 2.23 - 2.59
2 month 2.59 .51 .12 2.30-2.89
P value 0.001
PEFR
Study onset 73.29 7.99 1.94 69.18 – 77.40
End of study 88.41 7.50 1.82 84.55 – 92.27
P value 0.0001
Table 5. Combinee rates of all data for patients of Conventional treatment with Fexofenadine + Tianeptine [group 4]:
3.5. Comparison between the rates of the key points for all groups
The averages of PSS for all groups were roughly convergent (P>0.05). All patients in the four
groups have made improvement with lightly varying degrees in the first month, with the
exception of the third group. However, the percentage of improvement in patients of this group
in the first month was relatively low, but after two months the improvement became well.
Furthermore, the average improvement after a month of treatment course was with highly
significant differences between the groups (P=0.000). However, the average improvement after
2 month was with non significant differences between the groups (P=0.06). The same pattern
of differences was achieved for PEFR, however, the changes in PEFR were significantly
different between the groups. Although the severity of asthma was more in group 4, the
increase change was more prominent in this group as compared to other 3 groups.Table 6.
Variable Improvement PEFR PercentAfter 1 month After 2 month PEFR 1 PEFR 2 Change
Group 1 1.94 2.11 72.66 83.61 10.95
Group 2 1.93 2.40 77.40 89.13 11.73
Group 3 1.00 2.13 80.40 88.40 08.00
Group 4 2.41 2.58 73.20 88.41 15.21
P value
ANOVA 0.000 0.067 0.034 >0.05 <0.05
Improvment1: Mean rate of overall improvement in the group after the first month
Improvment2: Mean rate of overall improvement in the group after the second month
PEFR1: Mean rate of peak expiratory flow of the group at the beginning of the study
PEFR2: Mean rate of peak expiratory flow of the group at the end of the study
Change: Mean the difference between the rate of peak expiratory flow between the beginning and end of the study
Table 6. Improvement comparison between the treatment groups
Tianeptine as Add for Treatment of Asthma
http://dx.doi.org/10.5772/58917
39
The proportion of decreasing of the mean percentage change of daily “as-needed” inhaled β-
agonist using for patients of each group were 25.5%, 31.1%, 26.6% and 35.8% for
groups1,2,3,and 4 respectively. The present study demonstrated non significant differences in
proportion of decreasing between the 4 groups. However, all groups demonstrated significant
differences in proportion of decreasing inhaled β-agonist use at the end of the study as
compared to enrollement time. Table 7.
Variable Number
Difference number of salbutamol using between onset and end study
P value
Mean SD 95% Confidence interval Rate of decrease
Group 1 18 2.56 2.57 1.27 - 3.83 25.5% 0.001
Group 2 15 3.13 1.58 2.86 - 4.61 31.1% 0.000
Group 3 15 2.67 1.05 2.09 - 3.25 26.6% 0.000
Group 4 17 3.59 1.94 2.59 - 4.58 35.8% 0.000
P value
ANOVA >0.05 >0.05
Table 7. Proportion of decreasing of the mean percentage change of daily “as-needed” inhaled β-agonist using for
patients of for treatment groups
In conclusion, the 4 treatment course were effective therapeutic approaches for asthma
treatment, however, the combination of SYMBICORT (budesonide and formoterol inhalation)
or SEROTID (Salmeterol, fluticasone propionate) plus Tianeptine (12.5 mg) three time daily
and fexofenadine (180 mg) once daily was superior in treating severe asthma.
4. Discussion
Individuals with asthma have twice the risk of developing mood and anxiety disorders as
individuals without asthma and these psychological factors are associated with worse
outcomes and greater need for medical intervention. Similarly, asthma symptom onset and
exacerbation often occur during times of increased psychological stress. Remission from
depression, on the other hand, is associated with improvement in asthma symptoms and
decreased usage of asthma medication. Yet research aimed at understanding the biological
underpinnings of asthma has focused almost exclusively on the periphery. An extensive
literature documents the relationship between emotion and asthma, but little work has
explored the function of affective neural circuitry in asthma symptom expression.[30]
The present study indicated that in patients receiving Tianeptine plus conventional asthma
treatment (group 2) demonstrate a hsigigher decrease in the mean percentage change in daily
“as-needed” inhaled β-agonist use (31.1%) as compared to patients group receiving conven‐
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tional asthma treatment (group 1) only (25.5%). Also, there was a higher decrease in the mean
percentage change in daily “as-needed” inhaled β-agonist use (35.8%) in the fourth group
which given conventional treatment with fexofenadine plus tianeptine as compared to the
other 3 groups of treatment. However, using ANOVA analysis, the differences in percentage
change in daily "as –needed'' between the four groups were not statistically significant.
Furthermore, the percentage of change was highly significant for the four groups of treatment.
PEFR was improved significantly in the four groups, however, there was a significant
differences in changes between the four ngroups of treatment. Furthermore, the PEFR change
was more in group four (conventional + tianeptine + fexofenadine) and lowest in group 3
(singulair plus Tianeptine). The rate of improvement was highest in group 4 and lowest in
group 3 after one month of treatment course and the there was a highly significant differences
between the 4 groups in their rate of improvement. However, after 2 months of treatment there
was no significant differences between the groups in their rate of improvement. This could be
explasined on the basis that fexofenadine may exert antiinflammatory action that may
influence the clinical improvement [31-38]
In this study the impact of Tianeptine was clear through the big improvement in patients who
receice this medicine, as demonstrated in reduction of daily use and percent reduction of
salbutamol, percent changes in PEFR and rate of improvement in group 2,3 and 4. However,
the above parameters changes were lower in group of patients (group 3) receiving singulair
with Tianeptine. This could be due to that singulair acts as antiinflammatory, it does prevent
bronchoconstriction, but not relieve the present bronchoconstriction. In addition, it takes 3 -4
to reach high peak blood mean (Tmax)[39].
The therapeutic effect of Tianeptine in treatment of asthma may be contributed to its ability to
suppress proinflammatory cytokines, interference with cholinergic and serotoninergic
pathways, modulation of immune response and/or serotonin uptake by platelets and seroto‐
nergic axons at the central nervous system [40,41]. Serotonin induces bronchoconstriction via
peripheral and central pathways resulting in increasing colinergic activity and histamine
release[42]. These changes may explain why tianeptine has proven to be a powerful therapeutic
tool in controlling asthma as this study indicated of better improvement in groups (groups
2,3,and 4) receiving tinaneptine. During asthma attack, catacholamines and free serotonin (f-5-
HT), only f-5-HT levels correlated positively with pulmonary function clinical severity [43,44].
f-5-HT was taken up by pulmonary endocrine cells that were located at the parasympathetic
terminals. Pulmonary endocrine cells located at the parasympathetic terminals taken up f-5-
HT. Bronchial smooth muscle contracted due to effect of serotonin through potententiation of
acetylcholine [39]. However, postsynaptic receptors (5-HT3 and 5-HT4) that located at the
bronchial muscle mediated serotonin effects.
A reported studies [45,46] suggested that tinaneptine therapy reduce plasma f-5-HT, clinical
rating and increase in pulmonary function. While, asthma attach triggered by drugs that
increase f-5HT such as buspirone and serotonin-uptake inhibitors (like sertraline, paroxetine,
etc).[47-50]. However, the side effects of buspirone and serotonin inhibitors may be controlled
by atropine [51]. Dupon et al.[52] suggested that serotonin produced frequency- and concen‐
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tration-dependent facilitation of cholinergic contractions of human airways, which was
mimicked by both 5-HT3 and 5-HT4 agonists, and subsequently 5-HT facilitates cholinergic
contractions in the human airways. In addition, Tianeptine greatlly annulated pulmonary
vasoconstriction and bronchoconstriction that induced by drugs through their ability to
increase f-5HT serum levels [53-59]. Neuroepithelial autocrine serotonergic cells located at the
bronchopulmonary system release 5-HT under the effect of acetylcholine stimulation, while,
serotonin triggers acetylcholine release from the parasympathetic terminals [60].
Mood disordera are more common in individuals with atopy [13]. Through our study, we can
say Tianeptine definitely seems to improve the asthma as it reduced the severity of symptoms
and improved the daily functioning of a asthmatic patient and reduced absences from school
or work, with increase PEFR, whether that it was added to traditional medicines (budesonide
and formoterol inhalation or Salmeterol, fluticasone propionate)or Singulair or fexofenadine.
But Group who took the traditional medicines for asthma with the addition of tianeptine and
fexofenadine was better and their symptoms responded to treatment better than others. This
finding may be due to synergistic antiinflamatory effects that induced by combination of
Tianeptine and fexofenadine.
Tianeptine led to a clinical improvement of asthmatic symptoms in the second group, patients
who were given the tianeptine in addition to traditional medicine has with better improvement
as compared to the first group who took traditional medicines only. This suggests the positive
effect of this drug for patients with asthma, of course not as a single medicine, but certainly as
adjuvant drug to the essential approved medicines. The mechanism by which this positive
impact was induced may be due to its significant anxiolytic properties for patients with asthma
who worry more than others or due to positive association between free serotonin in plasma
and severity of asthma in symptomatic patients. As tianeptine was the only agent known to
both reduce free serotonin in plasma and enhance uptake in platelets,[45,46]. Previous studies
have shown that antidepressants may be of therapeutic value in asthma [61,62] as there is
increasing evidence that a biological linkage may exist between asthma and depression
[61,63,64]. A defect in the function of the autonomic nervous system such as alpha-adrenergic
and cholinergic hyperresponsiveness and beta-adrenergic hyporesponsiveness even distal
from the airways has been demonstrated in asthmatic patients, as well as in depression [61,64].
Antidepressants may have a therapeutic role in asthma by supressing proinflammatory
cytokines and preventing their brain effects [61,65]. They also interfere with cholinergic and
serotoninergic pathways, both centrally and peripherally. Most antidepressants also induce
adaptive changes in central monoaminergic neurotransmission, which itself might modulate
immune reactivity [61,65]. Tianeptine is an antidepressant drug that has been recently used
with success in the treatment of asthma. Tianeptine treats depression through the enhancement
of serotonin reuptake from the synaptic cleft by serotoninergic terminals. It works by a
mechanism that is just the pollar opposite of selective serotonin reuptake inhibition. It has been
reported that this substance provoked a dramatic disappearance of clinical symptoms and
improved the pulmonary function in asthmatic patients [61,66].
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Without the slightest doubt, the modern conventional medicine such as SYMBICORT (bude‐
sonide and formoterol inhalation) or SEROTID (Salmeterol, fluticasone propionate has
provided great benefit for patients with asthma and It shall be the basis of good treatment for
asthmatic patients in various degrees and severity. In the present study, these drugs had good
results and improved symptoms of patient and their live quality. These treatment approach
showed improvement in PEFR from 72.6% to 83.7%, with difference in the amount of 11% and
significant decrease in the mean percentage change in daily “as-needed” inhaled β-agonist use
of about 25%. Some randomised controlled trial comparing stable dose Seretide with Symbi‐
cort, given as an adjustable maintenance dose, in 706 adults with persistent asthma [67]. Over
one year, those taking Serotide experienced the equivalent of 24 more symptom-free days
compared to those taking symbicort. The overall incidence of asthma exacerbations (a severe
attack) was 47% lower in the Seretide group. Overall, the majority of exacerbations did not
result in hospitalisation. Morning peak expiratory flow was significantly higher with Seretide
and those taking Seretide experienced a significantly higher proportion of days free of rescue
medication use [67].
In the present study, the two drugs had similar results in controling asthma and these results
were better in group 4 (given conventional treatment with fexofenadine plus tianeptine). As
table 6 shows the extent of improvement after 2 months of treatment comparison between the
four groups, the improvement of patients in fourth group was significant. This finding support
existence of the synergistic role of fexofenadine with tianeptine and conventional asthma
treatment, where the improvement in PEFR was greater in fourth group patients who took the
both of drugs together with conventional course. In addition to traditional medicine fexofe‐
nadine has been shown to have an impact on inflammatory mediators, other than histamine,
such as decreasing the production of LTC4, LTD4, LTE4, PGE2, and PGF2α; and diminishing
eosinophil adherence, chemotaxis, and opsonization of particles.[68] These effects may
provide benefit to some of the inflammatory responses of an acute allergic reaction and provide
a basis for future development of H1 antagonists with stronger anti-inflammatory effects.[68]
Repeated dosing with fexofenadine (180mg) and montelukast (10 mg) as add-on therapy
improved AMP PC20 and other surrogate inflammatory markers along with asthma diary
outcomes in ICS-treated atopic asthmatic patients. [69]. However, in our study the patients of
third group [given Singulair (montelukast) plus Tianeptine] were less responsive and less
improved compared with other groups especially in the first month. This may be due to the
combination of Singulair (montelukast) plus tianeptine only without the addition of drugs
such as SYMBICORT or SEROTID. However, results of imrovement in group thee at the end
of second month was better compared with the same group in the first month. This confirms
preventive influence of Singulair, Montelukast in a long term-controller medication which
should not be substituted for short acting β-agonists. Furthermore, this finding suggest not to
use Singulair alone and to be used in combination with other prophylactic agent.
Montelukast is a preventive agent, which should be used in addition to other drugs for the
management of asthma. [39] Therefore, as it is well known and previously confirmed, monte‐
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lukast is effective as prophylactic drug and control of chronic asthmatic course for subjects aged
≥ 15 years, however, of no value as rescue treatment approach in acute attacks.[39]
The clinical benefit from adding Tianeptine to asthma therapy course may actually result in
new indications for antidepressants. They could also help in understanding some common
pathophysiological mechanisms existing between asthma and depression.[19]
The treatment for asthma and depression involves a coordinated approach that monitors both the
symptoms of asthma and depression including using an asthma action plan. It is important to find the
treatment that works best for each person. The most effective treatments are those that combine
psychological and medical care, medical monitoring, individualised asthma education and adequate
community support. It should be noted that while antidepressants seem to have no specific effect on
asthma symptoms or medication, the National Asthma Council recommends that people should not take
sedatives when having an acute attack of asthma as it may have an effect on breathing [70]
The natural course of asthma include a scenario of triggering phase followed by generation of
symptom and inflammation phase to form a vicious cycle of subsequent phases [71]. Consti‐
tutional predisposition to the development of neurogenic generator component is necessary
for asthma development. Although stress does not cause asthma, stress and asthma are
definitely linked. Asthma causes stress, and stress makes it more difficult to control asthma.
Even daily stress can make asthma symptoms worsen. The learning to change stress response
to decrease asthma symptoms is important. Equally important is prioritizing patient daily
schedule so he allow enough time to accomplish what the patient needs to do without feeling
pressured or overwhelmed [71]
The study limitation is the small numbers of patients in each group. However, the power
analysis calculated to determine the effect of sample size in each group. The power of analysis
was 0.89 for reduction in PEFR for all groups, while that of rate improvement were 0.54 for
group 2, 0.10 for group 3 and 0.72 for group 4. These findings indicated that sample size with
influence on the finding of group 3 only. However, the power of analysis for the differences
between the groups indicated a values of >0.97 for the 4 groups indicating non influence of
sample sizes on the results.
In conclusion, the present study indicated the therapeutic activity of Tianeptine as add on
drug in asthma control and treatment. The most effective combination course is that of
fexofenadine, Tianeptine and conventional beta agonist such as symbicort or serotid. Until
today, management of bronchial asthma was held in two main directions:Modification of
factors inducing allergic reaction and interference on the certain stages of allergic reaction; and
Interference with peripheral bronchial receptors. Both these directions do finally affect the
trigger factors. Based on the present study findings, We suggest a 3rd direction in the man‐
agement of bronchial asthma: application of antidepresion agents for the control of activity of
generator neurogenic mechanisms of bronchial asthma. This new approach leads to the
prevention of asthmatic attacks and opens up new perspectives for the management of this
disease
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